Vancomycin Pharmacokinetics and Pharmacodynamics during Short Daily Hemodialysis

被引:15
作者
Decker, Brian S. [1 ,2 ]
Kays, Michael B. [2 ,3 ,4 ]
Chambers, Mary [2 ]
Kraus, Michael A. [1 ,2 ]
Moe, Sharon M. [1 ,2 ]
Sowinski, Kevin M. [2 ,3 ,4 ]
机构
[1] Indiana Univ, Sch Med, Div Nephrol, Indianapolis, IN 46202 USA
[2] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA
[3] Purdue Univ, Coll Pharm, Dept Pharm Practice, Indianapolis, IN USA
[4] Purdue Univ, Coll Pharm, Dept Pharm Practice, W Lafayette, IN 47907 USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2010年 / 5卷 / 11期
关键词
RESISTANT STAPHYLOCOCCUS-AUREUS; HIGH-FLUX HEMODIALYSIS; CARE SAFETY NETWORK; CONVENTIONAL HEMODIALYSIS; ANTIMICROBIAL-RESISTANT; BACTERICIDAL ACTIVITY; BACTEREMIA; INFECTIONS; DIALYSIS; EFFICACY;
D O I
10.2215/CJN.03450410
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives: Short daily hemodialysis (SDHD) is an alternative to thrice-weekly HD because of its putative physiologic benefits. The purpose of this study was to investigate the effect of SDHD on the pharmacokinetics and pharmacodynamics of vancomycin. Design, setting, participants, & measurements: Six noninfected adults who had anuria and were treated with SDHD were studied and received four dialysis sessions over 4 days. After completion of the first SDHD, each patient received vancomycin 15 mg/kg by intravenous infusion. Blood samples were collected over the ensuing 3 days during each subsequent inter- and intradialytic period. Pharmacokinetic parameters were determined. Serum concentration-time profiles were simulated for four vancomycin regimens with maintenance doses administered after every other SDHD. Area under the serum-concentration time curve (AUC) from 0 to 48 hours, 48 to 96 hours, and 96 to 144 hours were calculated, and Monte Carlo simulations were performed to determine the probability of target attainment at an AUC/minimum inhibitory concentration (MIC) ratio >= 800 for each 48-hour AUC at MICs ranging from 0.5 to 2.0 mu g/ml. Results: Median (range) systemic clearance was 7.2 ml/min (5.3 to 10.0 ml/min), and dialytic clearance was 104 ml/min (94 to 106 ml/min). The steady-state volume of distribution was 55.4 L (34.8 to 77.2 L). At MICs <= 1 mu g/ml, probability of target attainment was >90% for each 48-hour AUC when vancomycin was administered as a 20-mg/kg loading dose followed by 10 mg/kg after every other SDHD. Conclusions: Vancomycin pharmacokinetic parameters in SDHD are consistent with data from thrice-weekly HD. A loading dose of 20 mg/kg followed by 10 mg/kg after every other SDHD provides adequate exposure for pathogens with MICs <= 1 mu g/ml. Clin J Am Soc Nephrol 5: 1981-1987, 2010. doi: 10.2215/CJN.03450410
引用
收藏
页码:1981 / 1987
页数:7
相关论文
共 39 条
[1]   Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis [J].
Ariano, RE ;
Fine, A ;
Sitar, DS ;
Rexrode, S ;
Zelenitsky, SA .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (04) :681-687
[2]   Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers:: A prospective, controlled study [J].
Ayus, JC ;
Mizani, MR ;
Achinger, SG ;
Thadhani, R ;
Go, AS ;
Lee, SK .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (09) :2778-2788
[3]   Use of vancomycin in high-flux hemodialysis: Experience with 130 courses of therapy [J].
Barth, RH ;
DeVincenzo, N .
KIDNEY INTERNATIONAL, 1996, 50 (03) :929-936
[4]   Antimicrobial-resistant, gram-positive bacteria among patients undergoing chronic hemodialysis [J].
D'Agata, EMC .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (10) :1212-1218
[5]  
D'Argenio DZ., 2009, ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software
[6]  
Fridkin SK, 2001, CLIN INFECT DIS, V32, P108, DOI 10.1086/317542
[7]   High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections -: Efficacy and toxicity [J].
Hidayat, Levita K. ;
Hsu, Donald I. ;
Quist, Ryan ;
Shriner, Kimberly A. ;
Wong-Beringer, Annie .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (19) :2138-2144
[8]   Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007 [J].
Hidron, Alicia I. ;
Edwards, Jonathan R. ;
Patel, Jean ;
Horan, Teresa C. ;
Sievert, Dawn M. ;
Pollock, Daniel A. ;
Fridkin, Scott K. .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2008, 29 (11) :996-1011
[9]   Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacterernia [J].
Howden, Benjamin P. ;
Johnson, Paul D. R. ;
Ward, Peter B. ;
Stinear, Timothy P. ;
Davies, John K. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (09) :3039-3047
[10]   Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility [J].
Howden, BP ;
Ward, PB ;
Charles, PGP ;
Korman, TM ;
Fuller, A ;
du Cros, P ;
Grabsch, EA ;
Roberts, SA ;
Robson, J ;
Read, K ;
Bak, N ;
Hurley, J ;
Johnson, PDR ;
Morris, AJ ;
Mayall, BC ;
Grayson, ML .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (04) :521-528